Regorafenib plus FOLFIRINOX as first-line treatment for patients with RAS-mutant metastatic colorectal cancer (FOLFIRINOX-R trial): a dose-escalation study

to related objects

Location
Deutsche Nationalbibliothek Frankfurt am Main
Extent
1 Online-Ressource.
Language
Englisch

Bibliographic citation
Regorafenib plus FOLFIRINOX as first-line treatment for patients with RAS-mutant metastatic colorectal cancer (FOLFIRINOX-R trial): a dose-escalation study ; volume:94 ; number:3 ; day:10 ; month:7 ; year:2024 ; pages:443-452 ; date:9.2024
Cancer chemotherapy and pharmacology ; 94, Heft 3 (10.7.2024), 443-452, 9.2024

Creator
Adenis, Antoine
Ghiringhelli, François
Gauthier, Ludovic
Mazard, Thibault
Evesque, Ludovic
Evrard, Alexandre
Chalbos, Patrick
Moussion, Aurore
Gourgou, Sophie
Ychou, Marc
Contributor
SpringerLink (Online service)

DOI
10.1007/s00280-024-04682-4
URN
urn:nbn:de:101:1-2412092110478.897572390951
Rights
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Last update
15.08.2025, 7:28 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Show original at data provider

Associated

  • Adenis, Antoine
  • Ghiringhelli, François
  • Gauthier, Ludovic
  • Mazard, Thibault
  • Evesque, Ludovic
  • Evrard, Alexandre
  • Chalbos, Patrick
  • Moussion, Aurore
  • Gourgou, Sophie
  • Ychou, Marc
  • SpringerLink (Online service)

Other Objects (12)

Incoherent dose-escalation in phase I trials using the escalation with overdose control approach

Incoherent dose-escalation in phase I trials using the escalation with overdose control approach

What does a modified-Fibonacci dose-escalation actually correspond to?

What does a modified-Fibonacci dose-escalation actually correspond to?

PK/PD modeling supports the dose-escalation decision in VIKING

PK/PD modeling supports the dose-escalation decision in VIKING

Phase I dose-escalation oncology trials with sequential multiple schedules

Phase I dose-escalation oncology trials with sequential multiple schedules

Intravesical liposomal tacrolimus for hemorrhagic cystitis: a phase 2a multicenter dose-escalation study

Intravesical liposomal tacrolimus for hemorrhagic cystitis: a phase 2a multicenter dose-escalation study

A dose-escalation ex vivo study on the effects of intracameral benzalkonium chloride in rabbits

A dose-escalation ex vivo study on the effects of intracameral benzalkonium chloride in rabbits

Mesenchymal Stem Cell Therapy in Acute Intracerebral Hemorrhage: A Dose-Escalation Safety and Tolerability Trial

Mesenchymal Stem Cell Therapy in Acute Intracerebral Hemorrhage: A Dose-Escalation Safety and Tolerability Trial

Coenzyme Q10 dose-escalation study in hemodialysis patients: safety, tolerability, and effect on oxidative stress

Coenzyme Q10 dose-escalation study in hemodialysis patients: safety, tolerability, and effect on oxidative stress

Phase 1 dose-escalation trial evaluating a group 2 influenza hemagglutinin stabilized stem nanoparticle vaccine

Phase 1 dose-escalation trial evaluating a group 2 influenza hemagglutinin stabilized stem nanoparticle vaccine

Safety and pharmacokinetics of cabazitaxel in patients with hepatic impairment: a phase I dose-escalation study

Safety and pharmacokinetics of cabazitaxel in patients with hepatic impairment: a phase I dose-escalation study

Phase I dose-escalation study of milademetan in patients with relapsed or refractory acute myeloid leukemia

Phase I dose-escalation study of milademetan in patients with relapsed or refractory acute myeloid leukemia

A novel Bayesian method for dual-agent Phase I dose-escalation studies using penalized D-optimality

A novel Bayesian method for dual-agent Phase I dose-escalation studies using penalized D-optimality

Related objects